Fonte: European Archives of Psychiatry and Clinical Neuroscience. Unidade: FM
Assuntos: DOENÇA DE ALZHEIMER, FÁRMACOS (SISTEMA NERVOSO CENTRAL), PROTEÍNAS QUINASES, FOSFOLIPASES A
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TALIB, L. L. et al. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients. European Archives of Psychiatry and Clinical Neuroscience, v. 265, n. 8, p. 701-706, 2015Tradução . . Disponível em: http://link.springer.com/article/10.1007/s00406-015-0600-6. Acesso em: 03 out. 2024.APA
Talib, L. L., Hototian, S. R., Joaquim, H. P. G., Forlenza, O. V., & Gattaz, W. F. (2015). Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients. European Archives of Psychiatry and Clinical Neuroscience, 265( 8), 701-706. doi:10.1007/s00406-015-0600-6NLM
Talib LL, Hototian SR, Joaquim HPG, Forlenza OV, Gattaz WF. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2015 ; 265( 8): 701-706.[citado 2024 out. 03 ] Available from: http://link.springer.com/article/10.1007/s00406-015-0600-6Vancouver
Talib LL, Hototian SR, Joaquim HPG, Forlenza OV, Gattaz WF. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2015 ; 265( 8): 701-706.[citado 2024 out. 03 ] Available from: http://link.springer.com/article/10.1007/s00406-015-0600-6
